Table 2

Number of persons, crude incidence, average follow-up time and HRs for the different cervical outcomes under study

Outcome definition	Cohort	Number of patients at risk	Mean follow-up	Number of events	Crude incidence per 100 000 person-years	HR*	HR*
First screening with normal result	TNFi	9072	3.29	4362	14 599	1.01 (0.98 to 1.05)
	Biologics-naive RA	33 253	3.57	10 958	9224	Ref	1.08 (1.06 to 1.10)
	General population	287 602	4.18	114 943	9556		Ref
CIN 1	TNFi	8943	6.10	52	95.3	1.23 (0.87 to 1.74)
	Biologics-naive RA	32 947	5.26	99	57.1	Ref	1.53 (1.23 to 1.89)
	General population	285 232	6.66	852	44.8		Ref
CIN 2+	TNFi	9018	6.11	75	136.0	1.36 (1.01 to 1.82)
	Biologics-naive RA	33 130	5.27	137	78.5	Ref	1.39 (1.16 to 1.66)
	General population	286 731	6.67	1332	69.7		Ref
Invasive cervical cancer, overall	TNFi	9629	6.15	14	23.7	2.10 (1.04 to 4.23)
	Biologics-naive RA	34 984	5.27	25	13.6	Ref	1.09 (0.71 to 1.65)
	General population	300 331	6.68	275	13.7		Ref
Invasive cervical cancer†	TNFi	107	6.76	1	138.2	‡
	Biologics-naive RA	260	5.47	2	140.6	Ref	‡
	General population	2119	6.72	5	35.1		Ref
Invasive cervical cancer§	TNFi	685	6.05	3	72.3	‡
	Biologics-naive RA	2036	5.06	4	38.8	Ref	‡
	General population	15 069	6.47	20	20.5		Ref
Invasive cervical cancer¶	TNFi	6418	6.50	10	24.0	3.77 (1.35 to 10.48)
Invasive cervical cancer¶	Biologics-naive RA	18 520	5.47	7	6.9	Ref	0.78 (0.36 to 1.70)
	General population	162 543	7.08	112	9.7		Ref

*Stratified on decade of birth and adjusted for educational level, number of cervical screens past five years, comorbidities, marital status and total days spent in hospital during last five years, also implicitly adjusted for age since age was used as the model's timescale.
†In individuals with a history of CIN 1 or CIN 2+ during the five years before start of follow-up.
‡Not computed due to low number of events.
§in individuals with a history of CIN 1 or CIN 2+ ever.
¶In individuals with a normal screening test as the most recent screening test less than five years before start of follow-up.
CIN, cervical intraepithelial neoplasia; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.